Exercise and Nutrition Interventions for Platinum Chemotherapy-induced Neuropathy R21

Phase 2

Recruiting

• Conditions: Chemotherapy-induced Peripheral Neuropathy
• Interventions: Behavioral: Nutrition Education; Behavioral: EXCAP Exercise

• Registration Number: NCT05452902
• Lead Sponsor: University of Maryland, Baltimore

Brief Summary

Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe side-effect of platinum-based chemotherapy, often used to treat gastrointestinal cancers. Unfortunately there are very limited treatments for CIPN. This is a phase II randomized controlled trial to test the preliminary efficacy of exercise vs. nutrition education on CIPN, to systematically investigate the potential roles of inflammation and interoception, and to obtain data with a more accurate effect size to inform a future study.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-07-06
• Study First Submitted QC: 2022-07-06
• Study First Posted: 2022-07-11
• Study Start: 2023-01-19
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-16
• Last Update Posted: 2024-12-19
• Primary Completion: 2025-08-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Nutrition Education	Nutrition Education	Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
EXCAP Exercise	EXCAP Exercise	Exercise for Cancer Patients (EXCAP©®) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.

Primary Outcome Measures

Name	Time	Method
CIPN-20 sensory subscale	Time point 2 (approximately 6 weeks), controlling for baseline value	CIPN-20 sensory subscale (Postma et al 2005). The subscale includes 9 questions, each rated 1-4, and the score ranges from 9-36 with larger values reflecting more severe (worse) symptoms of chemotherapy-induced peripheral neuropathy (CIPN).

Secondary Outcome Measures

Name	Time	Method
Cold-induced pain	Time point 2 (approx. 6 weeks) or time point 3 (approx. 12 weeks), controlling for baseline	Finger cold sensitivity using thermode
Numbness and tingling	Time point 2 (approx. 6 weeks) or time point 3 (approx. 12 weeks), controlling for baseline	Patient-reported severity of numbness/tingling (0-10). A larger value reflects more severe (worse) symptoms of chemotherapy-induced peripheral neuropathy (CIPN).
Sensory, motor, and autonomic symptoms of CIPN	Time point 2 (approx. 6 weeks) or time point 3 (approx. 12 weeks) or time point 4 (approx. 24 weeks), controlling for baseline	CIPN-20 total score (Postma et al 2005). The score includes 20 questions, each rated 1-4, and the score ranges from 20-80 with larger values reflecting more severe (worse) symptoms of chemotherapy-induced peripheral neuropathy (CIPN).
Sensory loss	Time point 2 (approx. 6 weeks) or time point 3 (approx. 12 weeks), controlling for baseline	Finger and toe tactile sensitivity using monofilaments
CIPN-20 sensory subscale	Time point 2 (approx. 6 weeks) or time point 3 (approx. 12 weeks) or time point 4 (approx. 24 weeks), controlling for baseline	CIPN-20 sensory subscale (Postma et al 2005). The subscale includes 9 questions, each rated 1-4, and the score ranges from 9-36 with larger values reflecting more severe (worse) symptoms of chemotherapy-induced peripheral neuropathy (CIPN).

Trial Locations

Locations (1)

University of Maryland Medical System; 🇺🇸 Baltimore, Maryland, United States